List of Excipients in Branded Drug PYLARIFY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Progenics Pharmaceuticals Inc	PYLARIFY	piflufolastat f-18	71258-022	ALCOHOL	2027-11-07
Progenics Pharmaceuticals Inc	PYLARIFY	piflufolastat f-18	71258-022	ISOTONIC SODIUM CHLORIDE SOLUTION	2027-11-07

PYLARIFY Excipient Strategy and Commercial Opportunities in Prostate Cancer Imaging

Last updated: September 14, 2026

PYLARIFY is a fluorine-18 radiopharmaceutical containing piflufolastat F 18, a prostate-specific membrane antigen, or PSMA, PET imaging agent. Its excipient strategy is narrow and functional: isotonicity, radiolysis control, chemical stability, and compatibility with short-lived radioactive distribution. The most attractive commercial opportunities are in validated stabilizer systems, sterile single-use packaging, radiopharmacy manufacturing, automated dose preparation, and supply-chain services rather than conventional high-volume excipient substitution.

What excipients are used in PYLARIFY?

The PYLARIFY prescribing information identifies ascorbic acid, sodium chloride, and ethanol among the inactive ingredients in the injectable formulation. The product is supplied as a sterile intravenous solution containing piflufolastat F 18 and is administered by intravenous injection for PET imaging of PSMA-positive lesions in prostate cancer. [1]

Formulation element	Strategic function	Commercial relevance
Ascorbic acid	Antioxidant and radiolysis-control agent	Potential source of differentiated low-metal, low-peroxide stabilizer systems
Sodium chloride	Isotonicity and injection compatibility	Commodity excipient with limited differentiation
Ethanol	Solvent and formulation aid	Requires control of residual level, container compatibility, and regulatory documentation
Water for injection	Injectable vehicle	Requires sterile, pyrogen-controlled supply
Fluorine-18	Radioactive imaging isotope	Drives short shelf life, distribution limits, and specialized manufacturing

The formulation has a different risk profile from a conventional small-molecule injection. Fluorine-18 has a physical half-life of approximately 110 minutes. Product quality, dose availability, and commercial value decline rapidly after production. The excipient system must therefore preserve chemical integrity during synthesis, release testing, shipment, and administration without introducing additional operational complexity. [1,2]

How does PYLARIFY’s excipient strategy support product performance?

The formulation must address three technical risks: radiolysis, metal-catalyzed degradation, and rapid product turnover.

Radiolysis control

High-energy beta particles and positrons generated by fluorine-18 can promote radiolysis of the active compound and surrounding formulation components. Antioxidants such as ascorbic acid can reduce oxidative degradation, although their concentration and purity must be controlled.

Commercially relevant specifications include:

• Low peroxide content
• Low trace-metal burden
• Controlled pH
• Low bioburden and endotoxin
• Consistent concentration across manufacturing sites
• Compatibility with automated synthesis equipment
• No material that interferes with radiochemical purity testing

Excipient suppliers with established pharmaceutical-grade ascorbic acid, low-metal processing, and detailed impurity controls have a stronger position than suppliers offering only a nominally compliant ingredient.

Isotonicity and injection tolerability

Sodium chloride provides a conventional route to an isotonic injectable formulation. The use of a familiar electrolyte reduces clinical and manufacturing complexity. Because the product is administered in small volumes, the commercial opportunity is unlikely to come from replacing sodium chloride with a novel tonicity agent.

The higher-value opportunity is supply assurance. Radiopharmaceutical manufacturers need reliable sterile excipient supply, short release timelines, and documentation that supports batch disposition under compressed manufacturing schedules.

Solvent and container compatibility

Ethanol can improve solubilization and support the formulation of the radiolabeled product. Its presence creates additional compatibility considerations involving:

• Extractables and leachables
• Elastomeric stopper performance
• Glass vial integrity
• Surface adsorption
• Automated dispensing equipment
• Residual solvent testing

A supplier that can provide validated compatibility data for Type I glass, coated stoppers, septa, and automated dose-dispensing systems can compete on more than price.

What formulation barriers limit excipient substitution?

The principal barrier is that PYLARIFY is a radioactive injectable with a short usable life. Conventional formulation-development economics do not apply.

A replacement excipient must pass several screens:

1. Chemical compatibility with piflufolastat F 18.
2. Compatibility with the radiolabeling process.
3. Stability during the available commercial shelf life.
4. Compatibility with sterile filtration and aseptic filling.
5. Compatibility with the final container closure system.
6. Preservation of radiochemical purity and chemical purity.
7. Compliance with FDA inactive-ingredient and injectable-product expectations.
8. Acceptance in the manufacturer’s validated process.

A technically superior excipient may have limited commercial value if it requires a long reformulation program. Lantheus Technologies, Inc., the commercial sponsor of PYLARIFY, has an incentive to minimize changes that could trigger process revalidation, comparability work, or regulatory interaction. [1,3]

This creates a strong incumbent advantage for qualified suppliers already integrated into the approved manufacturing process.

What commercial opportunities exist for PYLARIFY excipient suppliers?

Low-metal antioxidant systems

The most defensible excipient opportunity is a pharmaceutical-grade antioxidant platform designed for radiopharmaceuticals. Suppliers can differentiate through:

• Trace-metal specifications
• Peroxide limits
• Lot-to-lot consistency
• Stability data under radioactivity exposure
• Sterile or ready-to-use presentation
• Supply continuity from multiple manufacturing sites

The product need is not simply ascorbic acid. It is a documented antioxidant system that performs under radiolytic stress and fits the manufacturing process.

Ready-to-use sterile excipient solutions

Radiopharmacy operations face pressure to reduce manual compounding and improve batch reproducibility. Ready-to-use sterile solutions containing qualified excipients can reduce preparation steps and support decentralized production.

Potential offerings include:

• Sterile antioxidant solutions
• Prequalified sodium chloride and ethanol blends
• Single-use formulation packs
• Compendial-grade solutions with rapid release documentation
• Custom excipient concentrates for automated synthesis modules

The commercial value depends on reducing operational time without compromising the validated process.

Container-closure systems

The container is a major part of the formulation strategy. Suppliers can target:

• Low-adsorption vials
• Radiation-compatible elastomeric stoppers
• Shielded primary containers
• Preassembled sterile vial systems
• Closure systems tested for ethanol exposure
• Packaging that supports automated dose withdrawal

Container suppliers with radiopharmaceutical-specific extractables, leachables, and dose-retention data can command higher margins than commodity packaging vendors.

Automated dose preparation

PYLARIFY is used in PET imaging centers that require accurate dose measurement and timely administration. Dose calibrators, dispensing systems, and shielded delivery components are adjacent commercial opportunities.

The most attractive products combine:

• Automated withdrawal
• Activity-based dosing
• Integrated decay correction
• Bar-code traceability
• Radiation shielding
• Reduced operator exposure
• Electronic batch records

Excipient suppliers can partner with equipment manufacturers by validating formulation performance in automated systems.

Contract manufacturing and radiopharmacy services

The short half-life of fluorine-18 favors regional production and distribution. Commercial opportunities exist for:

• Contract radiopharmaceutical manufacturing
• Regional cyclotron and radiochemistry networks
• Sterile filling
• Quality-control testing
• Same-day distribution
• Hospital-based dose preparation
• Manufacturing technology transfer

For PYLARIFY, manufacturing proximity can be as important as raw-material cost. A modest reduction in excipient price does not offset a missed production window or delayed patient dose.

How does PYLARIFY’s formulation opportunity compare with conventional pharmaceuticals?

Factor	PYLARIFY	Conventional injectable
Active ingredient	Short-lived radiolabeled small molecule	Stable active ingredient
Primary formulation risk	Radiolysis and decay	Chemical and physical stability
Shelf life	Constrained by fluorine-18 half-life	Often months or years
Excipient differentiation	Process-specific and stability-driven	Often broader formulation design
Manufacturing model	Regional, time-sensitive production	Centralized commercial manufacturing
Packaging importance	High because of radiation and rapid use	Important but less time-critical
Substitution economics	Qualification and supply reliability dominate	Cost and formulation performance often dominate
Regulatory pathway	Radiopharmaceutical-specific quality expectations	Standard drug-product controls

Conventional excipient strategies often rely on scale, cost reduction, and broad formulation flexibility. PYLARIFY requires specialized supply-chain execution. The winning supplier is likely to be the one that reduces manufacturing risk, not necessarily the one with the lowest unit price.

What FDA regulatory issues affect PYLARIFY excipient commercialization?

PYLARIFY was approved by the FDA in May 2021 for PET imaging of PSMA-positive lesions in men with prostate cancer, including initial staging in selected patients and suspected recurrence based on elevated prostate-specific antigen levels. [3]

Excipient changes can affect:

• The approved composition
• Manufacturing controls
• Stability data
• Sterile manufacturing validation
• Container-closure qualification
• Radiochemical purity
• Chemical purity
• Impurity profiles
• Labeling and product specifications

A change to an inactive ingredient may require documentation under the applicable postapproval change framework. The regulatory burden depends on the nature of the change, its effect on product quality, and whether the change affects the approved manufacturing process or product specifications. FDA’s radiopharmaceutical guidance emphasizes control of identity, strength, quality, purity, and stability for radioactive drug products. [2]

Suppliers therefore need a regulatory package that includes:

• Drug Master File support where appropriate
• USP or equivalent compendial status
• Residual solvent data
• Elemental impurity data
• Microbial and endotoxin controls
• Stability data
• Manufacturing change-control commitments
• Site-quality documentation
• Excipient compatibility studies

What patent and exclusivity issues affect excipient opportunities?

The commercial opportunity in PYLARIFY excipients is unlikely to depend on a standalone patent covering sodium chloride, ethanol, or ascorbic acid. Those materials are established pharmaceutical ingredients. Differentiation is more likely to arise from:

• Proprietary antioxidant combinations
• Manufacturing controls that reduce radiolysis
• Specific excipient concentrations
• Container-closure combinations
• Automated preparation systems
• Radiolabeling and purification processes
• Stability-enhancing methods
• Use of formulation systems in specific radiopharmaceutical processes

A supplier should separate three forms of protection:

1. Composition protection: claims directed to a particular excipient combination or concentration range.
2. Process protection: claims directed to radiolabeling, purification, sterile filling, or dose preparation.
3. Know-how protection: undisclosed process parameters, impurity controls, and compatibility data.

Know-how may provide more practical protection than a broad formulation patent because the product has a short shelf life and the manufacturing process must operate reliably within a narrow time window.

No broad commercial conclusion should rely on an assumed freedom-to-operate position for PYLARIFY without a current patent-family and litigation review. The relevant analysis must distinguish patents covering piflufolastat, PSMA-targeting radiochemistry, manufacturing methods, formulations, and delivery systems.

What competitive products affect PYLARIFY’s commercial opportunity?

The principal competitive pressure comes from other PSMA-targeted PET agents rather than from excipient substitutes. FDA-approved PSMA PET products include:

• PYLARIFY, piflufolastat F 18
• Illuccix, gallium Ga 68 gozetotide
• Locametz, gallium Ga 68 gozetotide

The competing products use different radionuclides and manufacturing models. Fluorine-18 has a longer half-life than gallium-68, which can support broader distribution from regional production sites. Gallium-68 products may benefit from generator-based or local radiopharmacy models, depending on facility infrastructure. [3-5]

Commercial issue	PYLARIFY	Gallium-68 PSMA products
Radionuclide	Fluorine-18	Gallium-68
Half-life	Approximately 110 minutes	Approximately 68 minutes
Distribution model	Regional production and shipment	Local or regional generator/cyclotron model
Excipient opportunity	Stability, solvent, antioxidant, packaging	Kit formulation, generator compatibility, sterile preparation
Primary operational constraint	Cyclotron production and time-sensitive distribution	Generator or cyclotron access and dose preparation

The growth of PSMA PET imaging expands demand for specialized radiopharmacy infrastructure. It also creates a competitive market for validated excipients, sterile consumables, shielding, dose-management software, and contract manufacturing.

How strong is the commercial opportunity for PYLARIFY excipients?

The opportunity is strongest in high-value technical services and weakest in commodity ingredients.

Opportunity	Attractiveness	Main barrier
Commodity sodium chloride	Low	Price competition
Standard ethanol supply	Low to moderate	Limited differentiation
Pharmaceutical-grade ascorbic acid	Moderate	Multiple qualified suppliers
Low-metal antioxidant system	High	Validation and customer qualification
Radiation-compatible vial and stopper	High	Long qualification cycles
Sterile ready-to-use excipient solution	High	Aseptic manufacturing requirements
Automated dose-dispensing components	High	Equipment integration
Contract radiopharmacy manufacturing	High	Capital, licensing, and regional logistics
Formulation and stability consulting	Moderate to high	Dependence on specialized expertise

Revenue exposure is concentrated in the expanding PSMA PET market, but excipient suppliers capture only a small portion of total radiopharmaceutical economics. Their value increases when they control a qualified material, validated process, or integrated service that reduces failed batches and missed patient appointments.

Key Takeaways

• PYLARIFY uses a compact injectable excipient system centered on ascorbic acid, sodium chloride, ethanol, and water for injection.
• The main technical challenge is radiolysis control during production, distribution, and administration.
• Commodity excipients offer limited margin and weak differentiation.
• The strongest opportunities are low-metal antioxidant systems, sterile ready-to-use solutions, radiation-compatible container closures, and automated dose-preparation equipment.
• PYLARIFY’s short fluorine-18 half-life makes supply reliability and regional manufacturing more important than raw-material price.
• Formulation changes face process-validation, sterile manufacturing, stability, and regulatory requirements.
• Excipient-related intellectual property is more likely to involve specific combinations, manufacturing methods, packaging systems, or confidential know-how than basic ingredient ownership.
• Competing PSMA PET agents create a broader market for radiopharmaceutical manufacturing and supply-chain services.

FAQs

Can a new antioxidant replace ascorbic acid in PYLARIFY?

Potentially, but the replacement would require compatibility, radiolysis, stability, sterile-processing, and regulatory evaluation. A substitute must demonstrate a measurable advantage over the existing qualified formulation.

Is ethanol in PYLARIFY a major commercial opportunity?

Ethanol alone is unlikely to offer substantial differentiation because it is a widely used pharmaceutical solvent. The opportunity is stronger in validated ethanol-containing formulations and container-closure systems that maintain product quality.

Do PYLARIFY excipients create a generic-drug opportunity?

Not directly. The more realistic opportunity is supplying excipients, packaging, manufacturing services, or alternative radiopharmaceutical formulations to companies developing competing PSMA imaging products.

Why does packaging matter so much for PYLARIFY?

Packaging must support sterility, radioactive-product handling, dose recovery, operator protection, and compatibility with ethanol-containing formulations. A qualified vial and stopper system can become a meaningful manufacturing barrier.

Could hospital radiopharmacies manufacture an equivalent PYLARIFY product?

Any alternative product would require its own regulatory authorization, validated manufacturing process, quality controls, and supply of fluorine-18. Hospital preparation of an approved product is different from commercial manufacture of an equivalent drug.

References

1. U.S. Food and Drug Administration. (2021). PYLARIFY (piflufolastat F 18 injection) prescribing information.
2. U.S. Food and Drug Administration. (2024). PET drugs: Current good manufacturing practice and quality control procedures; guidance for industry.
3. U.S. Food and Drug Administration. (2021). FDA approves new imaging drug for prostate cancer.
4. U.S. Food and Drug Administration. (2021). ILLUCCIX (gallium Ga 68 gozetotide injection) prescribing information.
5. U.S. Food and Drug Administration. (2022). LOCAMETZ (gallium Ga 68 gozetotide) prescribing information.